NurExone Announces Transfer of Manufacturing of ExoPTEN Drug to GMP Manufacturer
Aug 02, 2024
Contract Type
partnership
HaifaBiotechnology
Description
NurExone Biologic Inc. has successfully transferred the manufacturing of the small interfering RNA (siRNA) sequence for its flagship ExoPTEN nanodrug to a German producer with Good Manufacturing Practice (GMP) capabilities, which is a significant milestone in its regenerative medicine efforts. The new GMP partner has validated the siRNA sequence, demonstrating potency and effectiveness comparable to the previous research-grade producer. This achievement establishes the foundation for future GMP manufacture of a potent and patented product, essential for clinical trials and commercial sale.
Company Information
Company
NurExone Biologic
Location
MINUS 1 ENTRY, GROUND FLOOR OF BLDG B
Haifa, Haifa District, Israel
About
NurExone Biologic is developing a revolutionary biological exosome based technology drug platform to treat damage in the Central Nerve System. The breakthrough exosome-based technology was proven in preclinical studies to have the potential to treat spinal cord injuries.
HaifaBiotechnology